medical cannabis – EarthyRealist.com

While Congress is expected to lift the federal prohibition on cannabis some day, Capitol Hill remains too occupied with other matters in the current fall session to take up the issue, marijuana business watchers said this week.

Questions around coming catalysts for the cannabis sector from Washington, D.C., have been frequent in recent conversations with investors, but with other items such as infrastructure, healthcare, and potential tax hike under debate, it’s unlikely lawmakers will act on any federal measures in the near future.

“Prospects for action on bills regarding federal cannabis to be passed in the fall seem to have waned,” Alliance Global Partners analyst Aaron Grey said Wednesday in a research note.

The next six months may still provide a window for some action in early 2022 before attention shifts to midterm elections later next year, Grey said.

See also: Pot and poppy paintings: Inside a cannabis lifestyle company’s ‘immersive’ Van Gogh exhibit

The extra time it takes for Congress to act will help ancillary cannabis companies such as Greenlane Holdings Inc. GNLN, +3.80% and GrowGeneration GRWG, -0.07% increase their market share ahead of increased competition that would follow federal legalization, he said. Grey rates both stocks a buy and said the valuations of multistate operators have been more favorable in recent months.

In terms of potential legislation, three camps have emerged in Congress.
Some Democrats want a more comprehensive solution such as the Cannabis Administration and Opportunity Act, penned by Democrat Senators Cory Booker, Ron Wyden and Chuck Schumer. The bill would seek to correct the damage caused by the War on Drugs in minority communities and address other social impact issues.

Recent Cannabis Articles

How Living More Economical Is Going To Help You SurviveJuly 20, 2022
The 3 Survival Shopping CategoriesJuly 15, 2022
Money Rules For Successful People (Part 2)July 7, 2022
Money Rules For Successful People (Part 1)July 6, 2022
The 5 Most Recession Proof IndustriesJuly 5, 2022
Surviving In America Will Now Consist Of People With Useful KnowledgeOr WealthJuly 5, 2022
Financial Tip Of The Day: 6/30/2022June 30, 2022
Self Care Is Being Self AwareJune 28, 2022
The End Of The Entrepreneur Is ComingJune 26, 2022
Las Vegas’ Economic Review: Surviving In The USAJune 25, 2022
Marijuana Businesses Could Soon Be Listed On Stock ExchangesJune 23, 2022
A Warning To Those Wanting To Quit Their Jobs During The Great ResignationJune 23, 2022

Get new content delivered directly to your inbox.

ALT (Advanced Liquid Technology) has entered into an agreement with UK-based medical cannabis provider Grow Group Plc to launch and market its liquid medical cannabis products across Europe.

ALT’s proprietary, fast-acting medical cannabis product is neutral in flavor, zero-calorie, sugar-free, vegan, keto, and paleo-friendly and are designed to allow for more effective delivery in comparison to other products such as tinctures and sprays.

*Advanced Liquid Technology medical cannabis products*.

Medical cannabis patients will reportedly benefit from a more rapid onset time of between 5-15 minutes and more efficient absorption. ALT’s water-compatible products are made using kinetically stabilized nanoemulsions which allow cannabinoids to be effectively absorbed by the body.

ALT offers precise dosing of cannabinoids, allowing patients and clinicians to tailor treatment based on individual needs and requirements for a range of health conditions.

“We are [honored] to partner with GROW in bringing ALT’s completely differentiated brand and liquid medical cannabis technologies to the European medical markets,” said ALT CEO Robert Davis.

“After successfully launching ALT into California in December 2020, we are excited to expand internationally, our first step towards becoming a global brand. ALT’s mission is to Enhance Human Potential and we will do so, one patient at a time, through the power of our liquid cannabis platform.”

Through its new partnership with Grow Group Plc, ALT aims to have a range of EU GMP-certified medical cannabis products available to European patients through prescription by early 2022.

Grow GroupPlc CEO, Ben Langley stated: “Grow’s mission is to bring medical cannabis products to all patients who need them.

“We strive to constantly improve and innovate on our product offering. With our leading position and unique experience we are very confident that with ALT’s new mode of administration, using liquid medical cannabis, we are going to make another leap forward in providing patients with the best products and solutions for their symptom management.”

Grow Group Plc recently announced the launch of a crowdfunding campaign with Seedrs, seeking £3.2 million ($3,740,080.00 USD) of investment from “socially conscious shareholders.”

Article By Emily Ledger – Canex.com UK